Literature DB >> 28364271

ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.

Luciana Possidente1, Matteo Landriscina2,3, Giuseppe Patitucci4, Ludovica Borgia4, Vittoria Lalinga4, Giulia Vita4.   

Abstract

Lung adenocarcinomas are characterized by a variety of genetic and epigenetic changes that lead to activation of specific signaling pathways. This allowed the classification of lung adenocarcinomas according to genetic alterations and the clinical development of novel anticancer agents that affect the activity of specific oncoproteins. In such a context, chromosomal rearrangements that cause constitutive activation of ALK gene define a category of lung adenocarcinomas that is amenable to targeted therapy with ALK inhibitors. Thus, a major issue of current research is to define the morphological and immunophenotypic features of lung ALK-rearranged adenocarcinomas to improve the selection of tumors suitable for molecular genotyping. ALK status was determined, by immunohistochemistry and fluorescence in situ hybridization, in 94 surgically resected lung adenocarcinomas and correlated with histomorphological parameters. Indeed, ALK rearrangement was observed in 10/94 (11%) lung adenocarcinomas and enriched in tumors with a predominant mucinous (46%; p < 0.05) and solid (29%; p < 0.05) pattern. By contrast, it was lacking or sporadically observed in lung adenocarcinomas with predominant acinar, papillary or lepidic pattern. Moreover, the presence of signet-ring cells was predominantly observed in ALK-rearranged tumors (47%; p < 0.05). These data suggest that ALK rearrangement is associated with specific and distinct clinical-pathological characters compared to other genotypes. Thus, the knowledge of these characteristics can improve the diagnostic accuracy and lead to a better understanding of the behavior of ALK-rearranged NSCLC.

Entities:  

Keywords:  ALK rearrangement; FISH analysis; Histomorphological parameters; Non-small cell lung adenocarcinomas

Mesh:

Substances:

Year:  2017        PMID: 28364271     DOI: 10.1007/s12032-017-0936-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  48 in total

1.  Comprehensive histologic analysis of ALK-rearranged lung carcinomas.

Authors:  Akihiko Yoshida; Koji Tsuta; Harumi Nakamura; Takashi Kohno; Fumiaki Takahashi; Hisao Asamura; Ikuo Sekine; Masashi Fukayama; Tatsuhiro Shibata; Koh Furuta; Hitoshi Tsuda
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

2.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

3.  Eml4-alk-positive lung adenocarcinoma with signet-ring cells.

Authors:  Akihiko Kawahara; Jun Akiba; Hideyuki Abe; Tomohiko Yamaguchi; Tomoki Taira; Koichi Azuma; Masayoshi Kage
Journal:  Diagn Cytopathol       Date:  2012-11-16       Impact factor: 1.582

4.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

Review 5.  Molecular profiling in non-small cell lung cancer: a step toward personalized medicine.

Authors:  Kirtee Raparia; Celina Villa; Malcolm M DeCamp; Jyoti D Patel; Minesh P Mehta
Journal:  Arch Pathol Lab Med       Date:  2013-04       Impact factor: 5.534

6.  ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

Authors:  Sanjay Popat; David Gonzalez; Toon Min; John Swansbury; Melissa Dainton; James G Croud; Alexandra J Rice; Andrew G Nicholson
Journal:  Lung Cancer       Date:  2011-08-19       Impact factor: 5.705

7.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

8.  Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

Authors:  Ryu Jokoji; Takashi Yamasaki; Seigo Minami; Kiyoshi Komuta; Yasushi Sakamaki; Kengo Takeuchi; Masahiko Tsujimoto
Journal:  J Clin Pathol       Date:  2010-10-09       Impact factor: 3.411

9.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Authors:  Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Authors:  Ying Li; Yongwen Li; Tong Yang; Sen Wei; Jing Wang; Min Wang; Yuli Wang; Qinghua Zhou; Hongyu Liu; Jun Chen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more
  6 in total

1.  Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma.

Authors:  Yinglei Liu; Xiangyun Ye; Yongfeng Yu; Shun Lu
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

2.  Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma.

Authors:  Yan Li; Yan Tan; Song Hu; Jun Xie; Zhantao Yan; Xian Zhang; Yun Zong; Han Han-Zhang; Qing Li; Chong Li
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

3.  Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma.

Authors:  Hyun Woo Jeon; Young-Du Kim; Sung Bo Sim; Mi Hyoung Moon
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

4.  Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.

Authors:  Rumeng Gu; Ziling Shi; Ting Duan; Meijun Song
Journal:  Onco Targets Ther       Date:  2021-10-21       Impact factor: 4.147

5.  Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma.

Authors:  Wenyu Zhai; Dachuan Liang; Fangfang Duan; Wingshing Wong; Qihang Yan; Li Gong; Renchun Lai; Shuqin Dai; Hao Long; Junye Wang
Journal:  Front Cell Dev Biol       Date:  2021-12-08

6.  Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement.

Authors:  Qiongqiong Gao; Pupu Li; Xiangli Jiang; Zhongli Zhan; Qingna Yan; Bo Zhang; Chun Huang
Journal:  Oncotarget       Date:  2017-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.